After 14 h treatment with bortezomib or melphalan, HPSE-high cells had significantly higher viability than the cells expressing mutated heparanase thereby demonstrating the importance of heparanase enzymatic activity in myeloma cell resistance to chemotherapy (Figure 2D). The gene discussed is HPSE; the disease is plasma cell myeloma.